Breaking News

BioMed X Launches Rapid Antiviral Response Platform

Aims to develop ultrafast new antiviral drug discovery, development and mass-manufacturing tools for rapid scale-up of new medications.

By: Contract Pharma

Contract Pharma Staff

BioMed X, an independent biomedical research institute, has launched its new Rapid Antiviral Response Platform (RAR). In response to the COVID-19 pandemic, BioMed X aims to develop a portfolio of ultrafast new antiviral drug discovery, development and mass-manufacturing tools that will allow the identification of a new viral pathogen to 10,000 doses of a safe and potent new medication in less than 6 months. The RAR Platform will be developed using BioMed X’s new innovation model which brings ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters